The opening salvo in what promises to be one of the hottest debates in the new Congress was fired January 29 during a day-long hearing in the House Committee on Oversight and Reform—how to lower the price of prescription drugs. And it didn’t take long to make it clear that patents are right in the middle of the scrum. The role of patents was a prominent part of the House hearing. While cursory nods were made to the importance of encouraging innovation, the witnesses discussed how patent exclusivity, thickets, and evergreening drove up prices while promoting the greater use of Patent Trial and Appeal Board (PTAB) reviews against drug patents. The Committee was assured that curtailing patents wouldn’t harm innovation because the National Institutes of Health (NIH) is such an important funder of life science R&D.
The post Patents in the Crosshairs During House Drug Pricing Debate appeared first on IPWatchdog.com | Patents & Patent Law.
Business
- Patents on Transactions Using Cryptocurrency: Square versus PayPal
- Managing the Perils of Public IP Company Ownership
- IPO Top 300, 2020: Slight Decreases in Patent Grants Due to Budgets, Not COVID
- Pardon Me? Levandowski Case Highlights Need for Proactive Approach to Avoid Trade Secret Problems in Hiring
- How Patents Enable Mavericks and Challenge Incumbents
Recent Posts
- Why the Patent Classification System Needs an Update
- Solutions for Promoting Patent Practitioner Diversity at the USPTO in the Battle Against Systemic Racism
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung